Dr. Kirk Campbell is the C. Mahlon Kline Professor of Medicine and Chief of the Renal-Electrolyte and Hypertension Division at the University of Pennsylvania Perelman School of Medicine. Prior to joining Penn, Dr. Campbell was a Professor of Medicine at Mount Sinai in New York where he held a number of leadership roles including serving as the founding Director of the Mount Sinai Center for Kidney Disease Innovation, Nephrology Fellowship Director and Vice Chair of the Department of Medicine.

Dr. Campbell leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease and clinical trials in the rare kidney disease space. The work centers on advancing the understanding of the underlying mechanisms involved in glomerular disease progression while identifying potential targets for therapeutic intervention. Key findings include the identification of dendrin and the Hippo pathways target Yes-associated protein (YAP) as regulators of podocyte survival and plasminogen as a targetable biomarker in glomerular disease. He has been a lead principal investigator and steering committee chair for clinical trials testing the safety and efficacy of agents in development for focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy and lupus nephritis. He received his medical degree from the University of Connecticut and completed a residency in internal medicine at Yale-New Haven Hospital. He then completed a clinical and research fellowship in Nephrology at the Mount Sinai Medical Center in New York.